Endo International plunges as blood pressure injection sales tumble
09/08/2022 16:29
** Shares of generic drugmaker Endo International Plc
ENDP.O plunge ~34% to $0.44 - top loser on the Nasdaq
Biotechnology index .NBI
** Co's Q2 net total revenue falls 20%, hit by weakness in
sales of its low blood pressure injection, Vasostrict
urn:newsml:reuters.com:*:nPn4PyjQ4a
** Vasostrict Q2 sales tumble about 82% on lower price and
competition from generic drugs
** Including session's fall, stock down ~88%, compared with
a ~12 decline in the Nasdaq Biotechnology index
(Reporting by Raghav Mahobe)
((Raghav.Mahobe@thomsonreuters.com;))
Recent news on Endo International
See all newsBrief: Endo International PLC Files For Offering Of Up To 31.1 Million Common Shares By The Selling Stockholders - SEC Filing
Brief: Par Pharmaceutical Issues Voluntary Nationwide Recall Of Seven Lots Of Treprostinil Injection
Brief: Endo International Says Wholly-Owned Subsidiary Endo Finance Priced Its $1.5 Bln Senior Secured Seven-Year Term Loan
Brief: Endo, Inc. Announces Pricing Of $1 Bln Of Senior Secured Notes
Brief: Endo Announces Proposed Private Offering Of Senior Secured Notes